Institution
Anthony Nolan
Nonprofit•London, England, United Kingdom•
About: Anthony Nolan is a nonprofit organization based out in London, England, United Kingdom. It is known for research contribution in the topics: Transplantation & Human leukocyte antigen. The organization has 230 authors who have published 272 publications receiving 13641 citations.
Papers published on a yearly basis
Papers
More filters
••
Anthony Nolan1, University of Oxford2, Biomedical Primate Research Centre3, Kettering University4, Hoffmann-La Roche5, University of Texas MD Anderson Cancer Center6, Fred Hutchinson Cancer Research Center7, University of Washington8, University of California, Los Angeles9, Hallym University10, University of Geneva11, National Marrow Donor Program12, Medical University of Vienna13, Stanford University14, Harvard University15, University of Cambridge16
TL;DR: This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports.
Abstract: The WHO Nomenclature Committee for Factors of the HLA System met following the 14th International HLA and Immunogenetics Workshop in Melbourne, Australia in December 2005 and Buzios, Brazil during the 15th International HLA and Immunogenetics Workshop in September 2008. This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports (1–18).
2,390 citations
••
TL;DR: The Immuno Polymorphism Database was developed to provide a centralized system for the study of polymorphism in genes of the immune system and continues to develop with new tools being added to address scientific developments, and to address user feedback and requests.
Abstract: The Immuno Polymorphism Database (IPD) was developed to provide a centralized system for the study of polymorphism in genes of the immune system. Through the IPD project we have established a central platform for the curation and publication of locus-specific databases involved either directly or related to the function of the Major Histocompatibility Complex in a number of different species. We have collaborated with specialist groups or nomenclature committees that curate the individual sections before they are submitted to IPD for online publication. IPD consists of five core databases, with the IMGT/HLA Database as the primary database. Through the work of the various nomenclature committees, the HLA Informatics Group and in collaboration with the European Bioinformatics Institute we are able to provide public access to this data through the website http://www.ebi.ac.uk/ipd/. The IPD project continues to develop with new tools being added to address scientific developments, such as Next Generation Sequencing, and to address user feedback and requests. Regular updates to the website ensure that new and confirmatory sequences are dispersed to the immunogenetics community, and the wider research and clinical communities.
1,577 citations
••
TL;DR: The challenge for the IPD-IMGT/HLA Database is to continue to provide a highly curated database of sequence variants, while supporting the increased number of submissions and complexity of sequences.
Abstract: The IPD-IMGT/HLA Database, http://www.ebi.ac.uk/ipd/imgt/hla/, currently contains over 25 000 allele sequence for 45 genes, which are located within the Major Histocompatibility Complex (MHC) of the human genome. This region is the most polymorphic region of the human genome, and the levels of polymorphism seen exceed most other genes. Some of the genes have several thousand variants and are now termed hyperpolymorphic, rather than just simply polymorphic. The IPD-IMGT/HLA Database has provided a stable, highly accessible, user-friendly repository for this information, providing the scientific and medical community access to the many variant sequences of this gene system, that are critical for the successful outcome of transplantation. The number of currently known variants, and dramatic increase in the number of new variants being identified has necessitated a dedicated resource with custom tools for curation and publication. The challenge for the database is to continue to provide a highly curated database of sequence variants, while supporting the increased number of submissions and complexity of sequences. In order to do this, traditional methods of accessing and presenting data will be challenged, and new methods will need to be utilized to keep pace with new discoveries.
1,025 citations
••
TL;DR: Findings show how KIR-HLA interactions shape the genetic and phenotypic KIR repertoires for both individual humans and the population.
Abstract: Interactions between killer cell immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I ligands regulate the development and response of human natural killer (NK) cells. Natural selection drove an allele-level group A KIR haplotype and the HLA-C1 ligand to unusually high frequency in the Japanese, who provide a particularly informative population for investigating the mechanisms by which KIR and HLA polymorphism influence NK cell repertoire and function. HLA class I ligands increase the frequencies of NK cells expressing cognate KIR, an effect modified by gene dose, KIR polymorphism, and the presence of other cognate ligand–receptor pairs. The five common Japanese KIR3DLI allotypes have distinguishable inhibitory capacity, frequency of cellular expression, and level of cell surface expression as measured by antibody binding. Although KIR haplotypes encoding 3DL1*001 or 3DL1*005, the strongest inhibitors, have no activating KIR, the dominant haplotype encodes a moderate inhibitor, 3DL1*01502, plus functional forms of the activating receptors 2DL4 and 2DS4. In the population, certain combinations of KIR and HLA class I ligand are overrepresented or underrepresented in women, but not men, and thus influence female fitness and survival. These findings show how KIR–HLA interactions shape the genetic and phenotypic KIR repertoires for both individual humans and the population.
518 citations
••
TL;DR: KIR genotyping of prospective donors, in addition to HLA typing, should be performed to identify HLA-matched donors with B KIR haplotypes to confer significant survival benefit to patients undergoing T-replete HCT for AML.
419 citations
Authors
Showing all 236 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ghulam J. Mufti | 88 | 687 | 30934 |
Nigel H. Russell | 76 | 502 | 21810 |
Steven G.E. Marsh | 65 | 487 | 20763 |
Frits van Rhee | 61 | 323 | 14983 |
Charles Craddock | 60 | 302 | 13660 |
James Robinson | 48 | 172 | 11429 |
John Barrett | 44 | 114 | 7428 |
Bronwen E. Shaw | 42 | 286 | 6191 |
Richard Szydlo | 41 | 166 | 4775 |
Nancy F. Hensel | 34 | 87 | 4754 |
Alejandro Madrigal | 29 | 101 | 3529 |
Lawrence S. Lamb | 28 | 88 | 2311 |
Susana Gómez | 27 | 69 | 1891 |
Ann-Margaret Little | 26 | 63 | 2443 |
J. Alejandro Madrigal | 26 | 105 | 2577 |